Evidence map›Paper›PMID 40301887›Full record

ArticleJournal of biomedical science2025

Characterization of binding affinity changes of SARS-CoV-2 omicron variant peptides to population-specific HLA.

Che-Mai Chang, Chang-Jiun Wu, Maxim Shkurnikov, Chin-Lin Guo, Wan-Chen Huang, Alexander Tonevitsky, Wei-Chiao Chang

Abstract read
In one paragraph

Article in Journal of biomedical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Che-Mai Chang *Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chang-Jiun Wu *Department of Pharmaceutical Sciences, School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Maxim ShkurnikovFaculty of Biology and Biotechnology, HSE University, Moscow, Russia.
Chin-Lin GuoInstitute of Physics, Academia Sinica, Taipei, Taiwan.
Wan-Chen HuangSingle-Molecule Biology Core Lab, Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
Alexander TonevitskyFaculty of Biology and Biotechnology, HSE University, Moscow, Russia.
Wei-Chiao ChangMaster Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. wcc@tmu.edu.tw.

Funding

Ministry of Education DP2-TMU-113-O-01National Research University Higher School of Economics A.T.National Research University Higher School of Economics M.S.National Science and Technology Council NSTC112-2320-B-038-026-MY3National Science and Technology Council NSTC113-2327-B-038-001Taipei Medical University 112-5812-004-400
6 · The paper itself

Abstract

backgroundThe evolution of SARS-CoV-2, particularly through new variants, presents significant global health challenges due to their potential for immune evasion and reduced vaccine effectiveness. This study aims to investigate the impact of mutations in the Spike protein of Omicron EG.5 and XBB.1.16 variants on the binding affinities of viral peptides to common human leukocyte antigen (HLA) class I and II alleles across Taiwanese, British, and Russian populations. Understanding these interactions is crucial for elucidating differences in immune responses and disease severity among diverse populations.

methodsWe updated the T-CoV portal to incorporate and analyze EG.5 and XBB.1.16 variants. Binding affinities between mutated Spike protein peptides and HLA class I and II alleles were predicted and compared across the three populations. Statistical analyses, including chi-squared tests, were conducted to assess the significance of binding affinity differences across the three populations and between HLA classes.

resultsOur findings revealed that mutations in the Spike protein had a more pronounced effect on HLA class II binding affinities than on HLA class I. While binding affinity profiles for HLA class I were largely consistent across populations, significant population-specific variations were observed for HLA class II alleles. Specifically, the British population exhibited lower proportions of tightly binding mutated peptides compared to the Taiwanese and Russian populations. Furthermore, substantial differences were identified in the binding affinity changes of mutated Spike peptides for HLA class II across Taiwanese, British, and Russian populations, as well as between the Omicron EG.5 and XBB.1.16 variants. Subsequent analyses revealed significant differences in the conservation and evolutionary trajectories of binding affinities between mutated Spike peptides and common HLA class II alleles, both between the EG.5 and XBB.1.16 variants and across the three populations for the XBB.1.16 variant.

conclusionsIn summary, Spike protein mutations in SARS-CoV-2 variants significantly influence immune responses by altering HLA-peptide interactions, with pronounced population-specific effects on HLA class II alleles. These findings underscore the critical role of HLA class II diversity in shaping immune responses and susceptibility to COVID-19. Integrating population-specific HLA profiles into vaccine development and public health strategies is essential for improving interventions against evolving SARS-CoV-2 variants.

Indexed as

COVID-19Histocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensSARS-CoV-2Spike Glycoprotein, CoronavirusHumansMutationPeptidesProtein BindingRussiaTaiwanUnited KingdomHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2HLAOmicron variantSARS-CoV-2Spike proteinT-CoV

Identifiers

PMID40301887
PMCPMC12039199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.